Nunzia Bernardini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1946176/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of dietâ€induced obesity. British Journal of Pharmacology, 2021, 178, 3924-3942.	2.7	9
2	Donepezil improves vascular function in a mouse model of Alzheimer's disease. Pharmacology Research and Perspectives, 2021, 9, e00871.	1.1	4
3	From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinson's disease. European Journal of Histochemistry, 2021, 65, .	0.6	6
4	Colonic dysmotility and inflammation associated with high fat diet-induced obesity: role of the enteric glia. Proceedings of the Nutrition Society, 2020, 79, .	0.4	0
5	Enteric Glia at the Crossroads between Intestinal Immune System and Epithelial Barrier: Implications for Parkinson Disease. International Journal of Molecular Sciences, 2020, 21, 9199.	1.8	35
6	Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship. Cells, 2020, 9, 1772.	1.8	22
7	Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. International Journal of Molecular Sciences, 2020, 21, 3523.	1.8	24
8	Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. Neurobiology of Disease, 2020, 139, 104821.	2.1	28
9	Intestinal epithelial barrier and neuromuscular compartment in health and disease. World Journal of Gastroenterology, 2020, 26, 1564-1597.	1.4	28
10	Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity. International Journal of Obesity, 2019, 43, 331-343.	1.6	27
11	Microvascular Endothelial Dysfunction in Patients with Obesity. Current Hypertension Reports, 2019, 21, 32.	1.5	53
12	Microvascular Endothelial Dysfunction in Human Obesity: Role of TNF- <i>α</i> . Journal of Clinical Endocrinology and Metabolism, 2019, 104, 341-348.	1.8	54
13	Aging Modulates the Influence of Arginase on Endothelial Dysfunction in Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2474-2483.	1.1	41
14	Cell-specific pattern of berberine pleiotropic effects on different human cell lines. Scientific Reports, 2018, 8, 10599.	1.6	34
15	The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity. PLoS ONE, 2018, 13, e0195502.	1.1	47
16	Eosinophilia – associated basal plasmacytosis: an early and sensitive histologic feature of inflammatory bowel disease. Apmis, 2017, 125, 179-183.	0.9	12
17	Colonic Dysmotility Associated with High Fat Diet-Induced Obesity: Role of the Enteric Glia. Gastroenterology, 2017, 152, S180.	0.6	1
18	Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. Neuropharmacology, 2017, 123, 22-33.	2.0	15

Nunzia Bernardini

#	Article	IF	CITATIONS
19	Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors. Purinergic Signalling, 2017, 13, 497-510.	1.1	30
20	Different Impact of Essential Hypertension on Structural and Functional Age-Related Vascular Changes. Hypertension, 2017, 69, 71-78.	1.3	63
21	Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models. Neurogastroenterology and Motility, 2016, 28, 1781-1791.	1.6	41
22	Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. Journal of Neuroinflammation, 2016, 13, 146.	3.1	77
23	Diverticular Disease of the Colon. Journal of Clinical Gastroenterology, 2016, 50, S6-S8.	1.1	12
24	Fibrotic and Vascular Remodelling of Colonic Wall in Patients with Active Ulcerative Colitis. Journal of Crohn's and Colitis, 2016, 10, 1194-1204.	0.6	50
25	Enteric Dysfunctions in Experimental Parkinsons Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 233-243.	1.3	49
26	Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon. PLoS ONE, 2015, 10, e0144630.	1.1	96
27	Myenteric plexitis: A frequent feature in patients undergoing surgery for colonic diverticular disease. United European Gastroenterology Journal, 2015, 3, 523-528.	1.6	10
28	An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis. Journal of Cellular and Molecular Medicine, 2015, 19, 485-500.	1.6	29
29	Ghrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of NAD(P)H oxidase. European Heart Journal, 2015, 36, ehv365.	1.0	30
30	Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence. Parkinsonism and Related Disorders, 2015, 21, 1407-1414.	1.1	56
31	Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease. British Journal of Pharmacology, 2014, 171, 3728-3740.	2.7	10
32	Response to Endothelial Nitric Oxide Synthase, Cyclooxygenase-2, and Essential Hypertension: Is There an Interaction?. Hypertension, 2013, 62, e16.	1.3	1
33	Rosuvastatin prevents angiotensin <scp>II</scp> â€induced vascular changes by inhibition of <scp>NAD</scp> (<scp>P</scp>) <scp>H</scp> oxidase and <scp>COX</scp> â€1. British Journal of Pharmacology, 2013, 169, 554-566.	2.7	18
34	Histopathology in Gastrointestinal Neuromuscular Diseases. Advances in Anatomic Pathology, 2013, 20, 17-31.	2.4	14
35	Endothelial Dysfunction in Small Arteries of Essential Hypertensive Patients. Hypertension, 2013, 62, 337-344.	1.3	97
36	Altered Expression Pattern of Molecular Factors Involved in Colonic Smooth Muscle Functions: An Immunohistochemical Study in Patients with Diverticular Disease. PLoS ONE, 2013, 8, e57023.	1.1	28

Nunzia Bernardini

#	Article	IF	CITATIONS
37	Vascular Dysfunction in a Mouse Model of Rett Syndrome and Effects of Curcumin Treatment. PLoS ONE, 2013, 8, e64863.	1.1	41
38	Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1 Plays a Role in the Impairing Effects of Cyclooxygenase Inhibitors on Gastric Ulcer Healing. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 140-149.	1.3	14
39	Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition. European Heart Journal, 2012, 33, 2225-2234.	1.0	28
40	Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. Journal of Cellular and Molecular Medicine, 2012, 16, 318-327.	1.6	88
41	Vascular Generation of Tumor Necrosis Factor-α Reduces Nitric Oxide Availability in Small Arteries From Visceral Fat of Obese Patients. Journal of the American College of Cardiology, 2011, 58, 238-247.	1.2	98
42	The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway. Medical Science Monitor, 2011, 17, SC1-SC5.	0.5	3
43	Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. , 2010, 125, 62-78.		27
44	Sortilin Is a Putative Postendocytic Receptor of Thyroglobulin. Endocrinology, 2009, 150, 509-518.	1.4	21
45	Quantitative evaluation of myenteric ganglion cells in normal human left colon: implications for histopathological analysis. Cell and Tissue Research, 2009, 336, 191-201.	1.5	24
46	Gelatin/PLLA Spongeâ€Like Scaffolds Allow Proliferation and Osteogenic Differentiation of Human Mesenchymal Stromal Cells. Macromolecular Bioscience, 2008, 8, 819-826.	2.1	24
47	Interaction of human gingival fibroblasts with PVA/gelatine sponges. Micron, 2008, 39, 569-579.	1.1	49
48	The β ₃ â€adrenoceptor agonist SR58611A ameliorates experimental colitis in rats. Neurogastroenterology and Motility, 2008, 20, 1030-1041.	1.6	44
49	Cyclooxygenase-1 Is Involved in Endothelial Dysfunction of Mesenteric Small Arteries From Angiotensin II–Infused Mice. Hypertension, 2007, 49, 679-686.	1.3	66
50	Gelatine/PLLA sponge-like scaffolds: morphological and biological characterization. Journal of Materials Science: Materials in Medicine, 2007, 18, 1399-1405.	1.7	34
51	TSH-Dependent Expression of the LDL Receptor–Associated Protein (RAP) in Thyroid Epithelial Cells. Thyroid, 2006, 16, 1097-1104.	2.4	5
52	Constitutive expression of cyclooxygenase-2 in the neuromuscular compartment of normal human colon. Neurogastroenterology and Motility, 2006, 18, 654-662.	1.6	25
53	Gelatine/PLLA sponge-like scaffolds: morphological and biological characterization. Journal of Materials Science: Materials in Medicine, 2006, 17, 1211-1217.	1.7	14
54	Role of Cyclooxygenase Isoforms and Nitric-Oxide Synthase in the Modulation of Tracheal Motor Responsiveness in Normal and Antigen-Sensitized Guinea Pigs. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 648-656.	1.3	2

NUNZIA BERNARDINI

#	Article	IF	CITATIONS
55	Differential Role of Cyclooxygenase 1 and 2 Isoforms in the Modulation of Colonic Neuromuscular Function in Experimental Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 938-945.	1.3	34
56	Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut, 2005, 54, 608-616.	6.1	52
57	Kidney Expression of RhoA, TGF-β1, and Fibronectin in Human IgA Nephropathy. Nephron Experimental Nephrology, 2005, 101, e16-e23.	2.4	12
58	Cyclooxygenase-2 Inhibition Improves Vascular Endothelial Dysfunction in a Rat Model of Endotoxic Shock: Role of Inducible Nitric-Oxide Synthase and Oxidative Stress. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 945-953.	1.3	92
59	Thyroid dysfunction in megalin deficient mice. Molecular and Cellular Endocrinology, 2005, 236, 43-47.	1.6	24
60	Involvement of metalloprotease-2 in the development of human brain microvessels. Histochemistry and Cell Biology, 2004, 122, 261-270.	0.8	31
61	Carboxy-terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA. Journal of Cellular Biochemistry, 2004, 93, 1231-1241.	1.2	17
62	Cellular and subcellular localization of the small G protein RhoA in the human and rat embryonic and adult kidney. Acta Histochemica, 2003, 105, 89-97.	0.9	10
63	Effect of heparan sulphate on kidney tissue expression of TGF-beta, rhoA, laminin and fibronectin in subtotally nephrectomized rats. Journal of Nephrology, 2002, 15, 530-8.	0.9	3
64	Renal cell cultures for the study of growth factor interactions underlying kidney organogenesis. In Vitro Cellular and Developmental Biology - Animal, 2001, 37, 251-258.	0.7	7
65	RENAL CELL CULTURES FOR THE STUDY OF GROWTH FACTOR INTERACTIONS UNDERLYING KIDNEY ORGANOGENESIS. In Vitro Cellular and Developmental Biology - Animal, 2001, 37, 251.	0.7	2
66	The Heparan Sulfate Suleparoide Inhibits Rat Corneal Angiogenesis and in vitro Neovascularization. Experimental Eye Research, 1998, 67, 133-142.	1.2	39
67	The Use of Mab 1977 Monoclonal Antibody for the Immunohistochemical Localization of β1 Integrins in Paraffin-Embedded Human Kidney. Tumori, 1997, 83, 673-678.	0.6	2
68	Immunohistochemical localization of the epidermal growth factor, transforming growth factor $\hat{l}\pm$, and their receptor in the human mesonephros and metanephros. , 1996, 206, 231-238.		34
69	The location and the regulation of the type I-iodothyronine 5′-monodeiodinase (type I-MD) in the rat thyroid: studies using a specific anti-type I-MD antibody. Molecular and Cellular Endocrinology, 1995, 110, 195-203.	1.6	10
70	Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4′-amino-3′-hydroxy-doxorubicin. Cancer Chemotherapy and Pharmacology, 1992, 29, 261-265.	1.1	8
71	Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Cancer Chemotherapy and Pharmacology, 1992, 30, 95-99.	1.1	26
72	Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heart. Toxicology, 1992, 75, 209-219.	2.0	7

#	Article	IF	CITATIONS
73	Cardiotoxicity and cytotoxicity of the anthracycline analog 4′-deoxy-4′-iodo-doxorubicin. Toxicology, 1991, 70, 243-253.	2.0	9
74	Cardiac toxicity and antitumor activity of 4′-deoxy-4′-iodo-doxorubicinol. Cancer Chemotherapy and Pharmacology, 1990, 26, 403-408.	1.1	9
75	Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats. Cancer Chemotherapy and Pharmacology, 1990, 25, 326-332.	1.1	20
76	Evaluation of the JT and corrected JT intervals as a new ECG method for monitoring doxorubicin cardiotoxicity in the dog. Journal of Pharmacological Methods, 1989, 21, 317-327.	0.7	4
77	Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue. European Journal of Cancer & Clinical Oncology, 1988, 24, 1123-1131.	0.9	13